Genmab — December 2020
-
-
and each time a think 'it is a shame those JNJ duobody royalties aren't a bit higher', I also realise that without JNJ Genmab would have possibly gone broke... And also how JNJ must feel for not buying the whole shop when they invested $80mio in 2012 lol
-
Again Janssen has done so much for driving this platform forward so we just hope that Genmab can continue this with epco, 4-1BBs and so forth. So much good stuff going on and things become rather complex.....but I just feel that it almost acnt go wrong no matter what
-
-
Ahhh, tak Bulder - jeg skal tage fra GENs side så: "Subcutaneous Epcoritamab Induces Complete Responses With an Encouraging Safety Profile Across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients With Prior CAR-T Therapy: Updated Dose-Escalation Data– Oral presentation, Sunday, December 6 12.30 PST" ?
-
Mateos discusses the preliminary results of
talquetamab https://www.youtube.com/watch?v=1Ib2V9m_MeU -
Hvordan skal man forstå tidspunktet her: "Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models– Poster presentation, Sunday, December 6, 7.00 AM – 3.30 PM PST." Kommer det bare på et eller andet tidspunkt i dag 16:00-0:30
?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind